<DOC>
	<DOCNO>NCT02329457</DOCNO>
	<brief_summary>Hematopoietic stem cell transplantation ( HSCT ) well-established therapy patient malignant hematological disease . Varicella zoster virus ( VZV ) reactivation , clinically manifest herpes zoster ( HZ ) , major complication affect 50 % patient . Most patient require hospitalization . Despite treatment high dose acyclovir , patient may develop severe complication include disable postherpetic neuralgia , corneal ulceration , viral dissemination secondary bacterial infection . The median onset infection fifth month follow transplantation , 91 % case occur within first year . Direct vaccination transplant recipients subcutaneous live-attenuated VZVv transplantation one year transplantation contraindicate . A small prospective non-randomized study demonstrate subcutaneous vaccination donor HSCT may offer protection VZV reactivation recipient . Recently , dose-sparing influenza vaccine deliver via novel intradermal microneedle show elicit good immunogenic response healthy elderly subject . We seek assess efficacy safety novel intradermal live-attenuated VZVv sibling donor undergo HSCT .</brief_summary>
	<brief_title>VZV Vaccine Hematopoietic Stem Cell Transplantation</brief_title>
	<detailed_description>Hematopoietic stem cell transplantation ( HSCT ) well-established therapy patient malignant hematological disease . Varicella zoster virus ( VZV ) reactivation , clinically manifest herpes zoster ( HZ ) , major complication affect 50 % patient . Most patient require hospitalization . Despite treatment high dose acyclovir , patient may develop severe complication include disable postherpetic neuralgia , corneal ulceration , viral dissemination secondary bacterial infection . The median onset infection fifth month follow transplantation , 91 % case occur within first year . Direct vaccination transplant recipients subcutaneous live-attenuated VZVv transplantation one year transplantation contraindicate . A small prospective non-randomized study demonstrate subcutaneous vaccination donor HSCT may offer protection VZV reactivation recipient . Recently , dose-sparing influenza vaccine deliver via novel intradermal microneedle show elicit good immunogenic response healthy elderly subject . We seek assess efficacy safety novel intradermal live-attenuated VZVv sibling donor undergo HSCT . We plan enroll 160 pair adult donor patient undergo allogeneic HLA match sibling HSCT prospective randomize double-blind placebo-controlled trial period 3 year . Enrolled donor patient randomize 4 group : Group 1 : intradermal reduce dose live-attenuated VZVv ; Group 2 : subcutaneous full dose live-attenuated VZVv ; Group 3 : intradermal 0.9 % normal saline control ; Group 4 : subcutaneous 0.9 % normal saline second control ; Group 5 : intradermal reduce dose live-attenuated VZVv topical imiquimod pretreatment . All vaccine give donor 28 day . All intradermal vaccine give via microneedle syringe . Both investigator participant blind randomization process . The primary end point safety immunological response donor . The secondary end point occurrence HZ patient within 12 month transplantation .</detailed_description>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Chickenpox</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>patient undergo allogeneic hemopoietic stem cell transplant HLA identical sibling donor participant willing provide write informed consent history zoster 12 month prior transplantation exposure VZV within 4 week transplantation neomycin sensitivity sensitivity component zoster vaccine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>double-blind , randomize , intradermal , VZVv , HSCT</keyword>
</DOC>